Congressional Hearing on the Trump Administration's Drug Crisis Response
January 1, 2019
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This hearing serves as a formal oversight mechanism to review federal drug policy and the allocation of resources for the Office of National Drug Control Policy, which impacts national public health strategies and funding for local drug trafficking task forces.
Potentially affected actors named in the source documents. Mention is not a position.
Office of National Drug Control Policy
The agency's policies and funding were subject to congressional review and oversight during this hearing.
General Public
The hearing addresses national public health strategies regarding drug overdoses, which impact healthcare and law enforcement services nationwide.
Last recorded activity January 1, 2019.
Next step not available in the current record.
Summary
Key Facts
- The hearing took place on March 7, 2019, in the Rayburn House Office Building.
- In 2017, more than 70,000 people died from drug overdoses in the United States.
- The committee previously passed bipartisan legislation to reauthorize the Office of National Drug Control Policy.
- The hearing included testimony from the Office of National Drug Control Policy, the Government Accountability Office, and the Houston High Intensity Drug Trafficking Area.
- Several documents were entered into the record, including the 2018 Houston HIDTA Threat Assessment Report and various articles on the opioid crisis.
Frequently Asked Questions
What was the purpose of this hearing?
Who testified at the hearing?
Why It Matters
This hearing serves as a formal oversight mechanism to review federal drug policy and the allocation of resources for the Office of National Drug Control Policy, which impacts national public health strategies and funding for local drug trafficking task forces.
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Bipartisan focus on drug policy
The hearing highlights a rare instance of bipartisan cooperation in the 116th Congress regarding the reauthorization of the Office of National Drug Control Policy.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy20Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools